undamentalytics Newsletter
Sign in

Prime Medicine, Inc. revenue

Prime Medicine, Inc.'s revenue was $4.6m in fiscal 2025, up 55.3% on the year before. Since fiscal 2020 ($5.2m) it has grown at a compound -2.3% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue5,2100002,9834,632
Growth on the year before—−100.0%———+55.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Prime Medicine, Inc. $4.6m 55.3% —
Ocugen, Inc. $4.6m -3.7% 26.3%
Entrada Therapeutics, Inc. $4.7m -94.1% —
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —

Compare with peers

Head to head: OCGN vs PRMEPRME vs TRDABOLT vs PRME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prime Medicine, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prime Medicine, Inc.